Patritumab deruxtecan
Patritumab deruxtecan is an investigational antibody-drug conjugate (ADC) designed for the treatment of various types of cancer. It is composed of a fully human anti-HER3 (human epidermal growth factor receptor 3) monoclonal antibody linked to a topoisomerase I inhibitor payload. This drug is being developed by Daiichi Sankyo in collaboration with AstraZeneca.
Mechanism of Action[edit | edit source]
Patritumab deruxtecan targets the HER3 receptor, which is overexpressed in several types of cancer, including non-small cell lung cancer (NSCLC) and certain types of breast cancer. Upon binding to HER3, the ADC is internalized by the cancer cell, where the linker is cleaved, releasing the cytotoxic payload. The released topoisomerase I inhibitor then induces DNA damage, leading to cell death.
Clinical Development[edit | edit source]
Patritumab deruxtecan is currently undergoing clinical trials to evaluate its efficacy and safety in various cancer types. Early-phase studies have shown promising results, particularly in patients with advanced or metastatic cancers that have become resistant to other treatments.
Non-Small Cell Lung Cancer[edit | edit source]
In NSCLC, patritumab deruxtecan is being investigated for its potential to treat patients who have progressed on prior therapies, including tyrosine kinase inhibitors and chemotherapy.
Breast Cancer[edit | edit source]
For breast cancer, particularly HER3-positive subtypes, patritumab deruxtecan is being studied as a potential treatment option for patients who have exhausted other therapeutic options.
Side Effects[edit | edit source]
As with other ADCs, patritumab deruxtecan can cause a range of side effects. Common adverse events include nausea, fatigue, and neutropenia. More serious side effects may include interstitial lung disease and severe myelosuppression.
Future Directions[edit | edit source]
Ongoing research aims to further elucidate the optimal use of patritumab deruxtecan, including combination therapies with other targeted agents and immunotherapies. The results of these studies will determine its potential role in the standard treatment regimens for various cancers.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
